3.40
Cytomx Therapeutics Inc stock is traded at $3.40, with a volume of 1.71M.
It is up +1.19% in the last 24 hours and up +70.00% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$3.36
Open:
$3.4359
24h Volume:
1.71M
Relative Volume:
0.52
Market Cap:
$560.70M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-170.00
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
+3.66%
1M Performance:
+70.00%
6M Performance:
+538.50%
1Y Performance:
+195.65%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CTMX
Cytomx Therapeutics Inc
|
3.40 | 554.11M | 101.21M | -569.00K | -56.88M | -0.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-22-25 | Initiated | Cantor Fitzgerald | Overweight |
Sep-17-25 | Resumed | Barclays | Overweight |
Jul-31-25 | Initiated | Oppenheimer | Outperform |
May-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
Apr-14-25 | Resumed | Piper Sandler | Overweight |
May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
May-06-24 | Upgrade | Jefferies | Hold → Buy |
Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
Nov-15-21 | Initiated | BTIG Research | Buy |
May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
Mar-29-21 | Initiated | JP Morgan | Overweight |
Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
May-14-20 | Reiterated | H.C. Wainwright | Buy |
Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
Mar-04-20 | Initiated | Barclays | Equal Weight |
Nov-20-19 | Initiated | Guggenheim | Buy |
Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
Jun-13-19 | Initiated | Mizuho | Buy |
May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
Mar-11-19 | Initiated | Barclays | Overweight |
Nov-26-18 | Initiated | Piper Jaffray | Overweight |
Oct-15-18 | Initiated | Goldman | Neutral |
Sep-13-18 | Initiated | H.C. Wainwright | Buy |
Jun-01-18 | Initiated | SunTrust | Buy |
Jan-05-18 | Initiated | Citigroup | Buy |
Sep-08-17 | Initiated | Wedbush | Outperform |
Mar-27-17 | Initiated | H.C. Wainwright | Buy |
Mar-02-17 | Initiated | Instinet | Buy |
Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
Has CytomX Therapeutics Inc. formed a bullish divergenceJuly 2025 Short Interest & Risk Controlled Daily Plans - newser.com
Intraday pattern recognizer results for CytomX Therapeutics Inc.2025 Year in Review & Reliable Volume Spike Trade Alerts - newser.com
Evaluating CytomX Therapeutics Inc. with trendline analysisQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com
CytomX Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 Fed Impact & Accurate Buy Signal Notifications - newser.com
Key metrics from CytomX Therapeutics Inc.’s quarterly data2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
Is CytomX Therapeutics Inc. meeting your algorithmic filter criteriaEarnings Risk Summary & High Accuracy Buy Signal Tips - newser.com
How CytomX Therapeutics Inc. stock compares to market leaders2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
Can CytomX Therapeutics Inc. rally from current levelsNew Guidance & AI Powered Market Trend Analysis - newser.com
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Shares Down 7%Should You Sell? - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Developing predictive dashboards with CytomX Therapeutics Inc. dataJuly 2025 Retail & AI Forecasted Entry and Exit Points - newser.com
CytomX Therapeutics (NASDAQ:CTMX) Raised to "Hold (C-)" at Weiss Ratings - MarketBeat
Custom watchlist performance reports with CytomX Therapeutics Inc.2025 Breakouts & Breakdowns & Real-Time Volume Triggers - newser.com
Why CytomX Therapeutics Inc. (6C1) stock is a strong analyst pickJuly 2025 Macro Moves & Entry and Exit Point Strategies - newser.com
Exit strategy if you’re trapped in CytomX Therapeutics Inc.Entry Point & Low Risk Entry Point Tips - newser.com
CytomX: A Fresh Start With New Drugs After Total Pipeline Failure (NASDAQ:CTMX) - Seeking Alpha
Will CytomX Therapeutics Inc. stock maintain dividend yieldPortfolio Profit Report & Reliable Price Breakout Alerts - newser.com
Detecting price anomalies in CytomX Therapeutics Inc. with AIEarnings Performance Report & Risk Managed Trade Strategies - newser.com
Is CytomX Therapeutics Inc. (6C1) stock attractive for growth fundsWeekly Market Outlook & Weekly Stock Performance Updates - newser.com
Multi factor analysis applied to CytomX Therapeutics Inc.July 2025 Breakouts & Precise Trade Entry Recommendations - newser.com
Risk adjusted return profile for CytomX Therapeutics Inc. analyzedMarket Trend Report & Intraday High Probability Setup Alerts - newser.com
Using AI based signals to follow CytomX Therapeutics Inc.2025 Buyback Activity & Precise Buy Zone Tips - newser.com
Will CytomX Therapeutics Inc. (6C1) stock beat international competitionTrade Volume Report & Free Technical Confirmation Trade Alerts - newser.com
CytomX Therapeutics Hits New 52-Week High of $3.48, Up 105.52% - Markets Mojo
CytomX Therapeutics Hits New 52-Week High at $3.28 - Markets Mojo
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Down 3.8%Should You Sell? - MarketBeat
Is CytomX Therapeutics Inc. stock ready for a breakoutQuarterly Risk Review & Weekly Chart Analysis and Trade Guides - newser.com
Will CytomX Therapeutics Inc. stock continue dividend increasesBuy Signal & Risk Controlled Stock Alerts - newser.com
Is CytomX Therapeutics Inc. stock reversal real or fakeQuarterly Portfolio Report & Expert Approved Momentum Trade Ideas - newser.com
What drives CytomX Therapeutics Inc stock priceStock Price Forecasts & Free Superior Trading Gains - earlytimes.in
What earnings margins imply for CytomX Therapeutics Inc. (6C1) stockJuly 2025 PostEarnings & Community Trade Idea Sharing Platform - newser.com
What technical signals suggest for CytomX Therapeutics Inc. stock - newser.com
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytomx Therapeutics Inc Stock (CTMX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Ogden Christopher | Chief Financial Officer |
Jun 16 '25 |
Sale |
2.69 |
10,614 |
28,540 |
226,271 |
Ogden Christopher | Chief Financial Officer |
Jun 13 '25 |
Sale |
2.95 |
1,641 |
4,841 |
199,385 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 13 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
286,136 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 16 '25 |
Sale |
2.69 |
13,884 |
37,334 |
272,252 |
McCarthy Sean A. | CEO |
Jun 13 '25 |
Option Exercise |
0.00 |
150,000 |
0 |
1,145,195 |
McCarthy Sean A. | CEO |
Jun 16 '25 |
Sale |
2.69 |
55,511 |
149,264 |
1,089,684 |
McCarthy Sean A. | CEO |
Mar 18 '25 |
Sale |
0.60 |
37,656 |
22,556 |
995,195 |
Ogden Christopher | Chief Financial Officer |
Mar 18 '25 |
Sale |
0.60 |
8,551 |
5,122 |
201,026 |
Chu Yu-Waye | Chief Medical Officer |
Mar 18 '25 |
Sale |
0.60 |
4,025 |
2,411 |
135,725 |
ROWLAND LLOYD A | General Counsel |
Mar 18 '25 |
Sale |
0.60 |
10,203 |
6,112 |
120,594 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):